Non–Shiga toxin-associated HUS (non–Stx-HUS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Non–Shiga toxin-associated HUS (non–Stx-HUS) comprises a heterogeneous group of patients in whom an infection by Stx-producing bacteria could be excluded as the cause of the disease. It can be sporadic or familial, with more than one family member affected by the disease and exposure to Stx-E. Coli excluded. Collectively, non–Stx-HUS forms have a poor outcome. Up to 50% of cases progress to ESRD or have irreversible brain damage, and 25% may die during the acute phase of the disease. After exposure to Stx-E. Coli, 38 to 61% of individuals, develop hemorrhagic colitis and 3 to 9% (in sporadic infections) to 20% progress to overt HUS. The average interval between E. coli exposure and illness is three days. Disease typically begins with abdominal cramps and nonbloody diarrhea; diarrhea may become hemorrhagic in 70% of cases, usually within 1 or 2 d. Vomiting occurs in 30 to 60% of cases, and fever occurs in 30%. Leukocyte count is generally elevated, and a barium enema may demonstrate “thumb-printing,” suggestive of edema and submucosal hemorrhage, especially in the ascending and transverse colon region. HUS is usually diagnosed 6 d after the onset of diarrhea.

·       The overall incidence of Non–Shiga toxin-associated HUS (non–Stx-HUS) is estimated to be 2.1 cases per 100,000 persons/yr, with a peak incidence ranging from 5 to 7 per 100,000 in children aged 5 yr and the lowest rate in adults.

Thelansis’s “Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non–Shiga toxin-associated HUS (non–Stx-HUS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Non–Shiga toxin-associated HUS (non–Stx-HUS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non–Shiga toxin-associated HUS (non–Stx-HUS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non–Shiga toxin-associated HUS (non–Stx-HUS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032